Research To Practice | Oncology Videos

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in EGFR-Mutant Non-Small Cell Lung Cancer | Faculty Presentation 1: Management of Metastatic EGFR Mutation-Positive NSCLC — Enriqueta Felip, MD, PhD CME information and select publications

Featuring an interview with Dr Saad Zafar Usmani, including the following topics: Optimizing treatment intervention for patients with newly diagnosed multiple myeloma (MM) (0:00) Role of anti-CD38 antibodies in induction and maintenance therapy for patients with newly diagnosed disease (4:22) Case: A woman in her late 70s with revised International Staging System (R-ISS) Stage II IgG kappa myeloma who received D-Rd followed by maintenance daratumumab (14:02) Case: A man in his early 60s with double-hit myeloma who received D-KRd and carfilzomib maintenance therapy (26:10) Case: A man in his early 70s with R-ISS Stage III IgG kappa myeloma and translocation (4;14) who deferred transplant (33:24) Future directions in the management of MM (40:37) CME information and select publications

Featuring a slide presentation and related discussion from Dr Saad Zafar Usmani, including the following topics: Evolution of therapeutic decision-making for patients with newly diagnosed multiple myeloma (MM) (0:00) Quadruplet therapy for transplant-eligible patients with newly diagnosed MM (6:26) Daratumumab with lenalidomide as maintenance therapy after transplant in newly diagnosed MM (16:16) Therapeutic options for transplant-ineligible patients with MM (19:51) CME information and select publications

Featuring an interview with Dr Seth Wander, including the following topics: The clinical utility of ESR1 mutations in HR-positive, HER2-negative advanced breast cancer Grinshpun A et al. The clinical utility of ESR1 mutations in hormone receptor-positive, HER2-negative advanced breast cancer. Hematol Oncol Clin North Am 2023;37(1):169-81. Abstract (0:00) Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and in combination with targeted therapy for ER-positive, HER2-negative advanced breast cancer Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and in combination with targeted therapy in estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Phase Ia/Ib EMBER study. J Clin Oncol 2024;[Online ahead of print]. Abstract (6:01) EORTC-2129-BCG: Elacestrant for ER-positive/HER2-negative breast cancer patients with ctDNA relapse Ignatiadis M et al. EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA). ESMO 2024;Abstract 338TiP. (8:20) CME information and select publications

Featuring perspectives from Dr Jennifer Woyach, including the following topics: AMPLIFY — First-Line Trials Combining Bruton Tyrosine Kinase (BTK) Inhibitors with Venetoclax Introduction (0:00) Case: An African American man in his mid 40s with progressive lymphadenopathy in the neck is diagnosed with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with trisomy 12 and an SF3B1 mutation — Erik Rupard, MD (1:50) Pirtobrutinib Questions for the Faculty: Effectiveness and tolerability of pirtobrutinib for patients with CLL and disease progression on prior BTK inhibition — Zanetta S Lamar, MD (21:18) Choice of First-Line BTK Inhibitor Case: A woman in her mid 80s diagnosed with CLL more than 30 years ago now has relapsed/refractory, ibrutinib-intolerant disease — Warren S Brenner, MD (31:29) Cardiotoxicity of BTK Inhibitors Case: A man in his early 70s with chronic atrial fibrillation requiring long-term anticoagulation is diagnosed with IGHV-unmutated CLL with del(13q), del(17p) and an XPO1 mutation — Bhavana (Tina) Bhatnagar, DO (34:53) Case: A man in his mid 70s with trisomy 12, IGHV-unmutated CLL has a history of congestive heart failure (ejection fraction 20% to 25%) resulting in multiple hospital admissions — Laurie Matt-Amaral, MD, MPH (37:51) CLL and COVID-19 Vaccinations; Role of MRD Testing; Anti-CD20 Antibodies Case: A man in his early 60s with CLL receives first-line obinutuzumab/venetoclax and has a moderate infusion reaction to obinutuzumab — Dr Rupard (41:17) Case: A man in his early 60s with CLL and well controlled autoimmune hemolytic anemia on ibrutinib is switched to zanubrutinib — Dr Lamar (45:26) Questions for the Faculty: CLL and COVID-19 vaccinations; role of MRD testing; anti-CD20 antibodies — Dr Brenner (49:23) Case: An Amish man in his mid 60s requires treatment for CLL but is paying for treatment "out of pocket" — Dr Rupard (55:33) CME information and select publications

Featuring perspectives from Dr Lisa Carey and Dr Rita Nanda, including the following topics: Introduction (0:00) Patient Videos and Clinical Investigator Survey (3:26) San Antonio Breast Cancer Symposium (SABCS®) Report — Education Session on Antibody-Drug Conjugates (26:03) Patient Videos and Clinical Investigator Survey (43:27) SABCS Report — Abstracts of Interest (55:56) Patient Videos and Clinical Investigator Survey (56:27) CME information and select publications

Featuring perspectives from Dr Lisa A Carey and Dr Rita Nanda, including the following topics: Introduction (0:00) Stages of Triple-Negative Breast Cancer (TNBC); Recurrence After Adjuvant Treatment (5:28) Long-Term Outcomes with Metastatic TNBC (11:55) Side Effects and Complications of Treatment (24:42) Dose Reduction (30:27) Working While Receiving Treatment (32:24) Support for Minor Children and Grandchildren (37:12) Second Opinions and Self Advocacy (42:53) Recording Clinic Visits; Complementary Therapies; Nutrition (48:38) Living Wills and Advanced Directives (55:41) Please take our survey

Featuring perspectives from Dr Jeremy S Abramson, Dr Jennifer Crombie, Prof Martin Hutchings, Dr Matthew Lunning and Dr Tycel Phillips, moderated by Dr Abramson, including the following topics: Introduction (0:00) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Abramson (2:17) Bispecific Antibody Therapy for DLBCL — Prof Hutchings (28:51) CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Lunning (52:01) Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes — Dr Phillips (1:17:46) Tolerability Considerations with CAR T-Cell and Bispecific Antibody Therapy — Dr Crombie (1:41:44) CME information and select publications

Featuring perspectives from Dr Alexander Perl, Dr Eytan M Stein, Dr Richard M Stone, Dr Eunice S Wang and Prof Andrew H Wei, moderated by Dr Stein, including the following topics: Introduction (0:00) Current Clinical Decision-Making for Myelofibrosis (MF) in the Absence of Severe Cytopenias — Dr Kuykendall (2:53) Managing MF for Patients with Thrombocytopenia — Dr Bose (32:45) Managing MF for Patients with Anemia — Dr Yacoub (59:47) Future Directions in the Management of MF — Dr Fleischman (1:27:53) CME information and select publications

Featuring perspectives from Dr Erika Hamilton, Dr Kevin Kalinsky, Dr Ian E Krop, Dr Joyce O'Shaughnessy and Dr Sara M Tolaney, including the following topics: Introduction (0:00) Optimizing the Care of Patients with HER2-Positive Metastatic Breast Cancer (mBC) — Dr Krop (10:17) Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer — Dr Tolaney (37:54) Integrating Novel Agents and Approaches into the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Kalinsky (53:59) Tolerability Considerations with Approved and Investigational Antibody-Drug Conjugates — Dr O'Shaughnessy (1:14:16) Other Important Care Considerations for Patients with mBC — Dr Hamilton (1:41:30) CME information and select publications